ATE483815T1 - Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren - Google Patents

Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren

Info

Publication number
ATE483815T1
ATE483815T1 AT05810305T AT05810305T ATE483815T1 AT E483815 T1 ATE483815 T1 AT E483815T1 AT 05810305 T AT05810305 T AT 05810305T AT 05810305 T AT05810305 T AT 05810305T AT E483815 T1 ATE483815 T1 AT E483815T1
Authority
AT
Austria
Prior art keywords
polymerase iii
expression constructs
iii promoters
rna polymerase
multiple rna
Prior art date
Application number
AT05810305T
Other languages
English (en)
Inventor
Catherine J Pachuk
Daniel E Mccallus
Chandrasekhar Satishchandran
Martin D Sigg
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE483815T1 publication Critical patent/ATE483815T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05810305T 2004-08-23 2005-08-23 Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren ATE483815T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60362204P 2004-08-23 2004-08-23
US62994204P 2004-11-22 2004-11-22
PCT/US2005/029976 WO2006033756A2 (en) 2004-08-23 2005-08-23 Multiple rna polymerase iii promoter expression constructs

Publications (1)

Publication Number Publication Date
ATE483815T1 true ATE483815T1 (de) 2010-10-15

Family

ID=36090440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05810305T ATE483815T1 (de) 2004-08-23 2005-08-23 Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren

Country Status (8)

Country Link
US (2) US7985581B2 (de)
EP (3) EP2270161A3 (de)
JP (1) JP4804467B2 (de)
AT (1) ATE483815T1 (de)
AU (1) AU2005287365B2 (de)
CA (1) CA2577519A1 (de)
DE (1) DE602005024015D1 (de)
WO (1) WO2006033756A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
EP2270162B1 (de) * 2003-06-12 2018-10-03 Alnylam Pharmaceuticals Inc. Konservierte hbv- und hcv-sequenzen zur genausschaltung
AU2016202897A1 (en) * 2004-12-22 2016-05-19 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
EP2316942B1 (de) * 2004-12-22 2021-04-21 Alnylam Pharmaceuticals, Inc. Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
JP2008237023A (ja) * 2005-07-15 2008-10-09 Univ Of Tokyo 多重ｓｈＲＮＡ発現ベクター
WO2008147430A2 (en) * 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
DK2548438T3 (en) 2006-11-08 2015-10-19 Veritas Bio LLC IN VIVO SUBMITTING DOUBLE-STRENGTH RNA TO A CELL
WO2008148068A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
US9029341B2 (en) * 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
US20130064881A1 (en) * 2011-09-08 2013-03-14 Gradalis, Inc. Compositions and methods for treating prostate cancer
WO2013067050A1 (en) 2011-10-31 2013-05-10 University Of Utah Research Foundation Genetic alterations in glioblastoma
CN104394892B (zh) * 2012-05-15 2020-02-14 北京命码生科科技有限公司 植物作为功能microRNA和/或功能siRNA运载体、制备方法及其应用
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
US11339437B2 (en) * 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
ES2745769T3 (es) 2014-03-10 2020-03-03 Editas Medicine Inc Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
WO2016073559A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing
KR102545316B1 (ko) 2014-11-10 2023-06-22 알닐람 파마슈티칼스 인코포레이티드 Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
US11267842B2 (en) 2015-03-03 2022-03-08 The Regents Of The University Of California Enzymatic modification of nucleic acids
TWI554608B (zh) * 2015-03-27 2016-10-21 Univ China Medical A nucleic acid sequence segment for enhancing protein expression, an expression vector comprising a sequence segment thereof, and a kit comprising its expression vector
WO2017177029A1 (en) * 2016-04-06 2017-10-12 Duke University Compositions and methods for enhanced gene expression and viral replication
BR112019001887A2 (pt) 2016-08-02 2019-07-09 Editas Medicine Inc composições e métodos para o tratamento de doença associada a cep290
EP3496727A4 (de) * 2016-08-12 2020-03-18 The Regents of the University of California Konstrukte und verfahren zur signalverstärkung
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
DK3768846T5 (da) * 2018-03-21 2024-08-19 Aldevron L L C Virale og ikke-virale nanoplasmidvektorer med forbedret produktion
EP3833766A1 (de) * 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nukleinsäuremoleküle und verwendungen davon zur nichtviralen gentherapie
JP7625512B2 (ja) 2018-08-13 2025-02-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
US20220195428A1 (en) * 2019-01-29 2022-06-23 The Genera Hospital Corporation Oligonucleotides and methods for the treatment of age-related macular degeneration
CN114277030B (zh) * 2021-12-28 2024-07-16 滨州医学院 一种pri-miRNA改良序列及表达该序列的载体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5547862A (en) 1993-07-29 1996-08-20 Ambion Inc. Vectors containing multiple promoters in the same orientation
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
EP0728202A4 (de) 1993-11-12 1997-04-23 Univ Case Western Reserve Episomales expressionsvektor für die menschliche gentherapy
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5585263A (en) 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5932241A (en) 1995-06-07 1999-08-03 Valentis, Incorporated Cationic lipid DNA complexes for gene targeting
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
AU7450496A (en) 1995-10-20 1997-05-07 Collagen Corporation Production of recombinant procollagen in yeast
US5851804A (en) 1996-05-06 1998-12-22 Apollon, Inc. Chimeric kanamycin resistance gene
KR20000068934A (ko) 1996-11-08 2000-11-25 스티븐 로쓰 개선된 발현 벡터
US5874242A (en) 1997-03-19 1999-02-23 University Of Georgia Research Foundation, Inc. Efficient translation in eukaryotic and prokaryotic systems
AU745805B2 (en) 1997-10-28 2002-04-11 Wyeth Compositions and methods for delivery of genetic material
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR20010041902A (ko) 1998-03-16 2001-05-25 데이비드 엠 모이어 포유류의 피부 내의 셀룰라이트를 감소시키는 방법
KR20070118315A (ko) 1999-04-21 2007-12-14 와이어쓰 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
JP2003269028A (ja) 2002-03-18 2003-09-25 Aisin Seiki Co Ltd ドアロック解除装置
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
EP1540004A4 (de) 2002-07-31 2007-10-03 Nucleonics Inc Doppelstrang-rna-strukturen und -konstrukte sowie verfahren zur erzeugung und verwendung davon
US7303906B2 (en) 2002-09-06 2007-12-04 Wisconsin Alumni Research Foundation Competent bacteria
CA2502649A1 (en) 2002-10-18 2004-04-29 Nucleonics Inc. Double-stranded rna structures and constructs, and methods for generating and using the same
ATE554185T1 (de) 2003-02-27 2012-05-15 Alnylam Pharmaceuticals Inc Verfahren und konstrukte zur bewertung von rnai- zielen und effektormolekülen
EP2270162B1 (de) 2003-06-12 2018-10-03 Alnylam Pharmaceuticals Inc. Konservierte hbv- und hcv-sequenzen zur genausschaltung
WO2005007875A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Enhanced promoters for synthesis of small hairpin rna
WO2005007877A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Regulatable promoters for synthesis of small hairpin rna
WO2005040388A2 (en) 2003-08-22 2005-05-06 Nucleonics Inc. Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
WO2005035718A2 (en) * 2003-10-03 2005-04-21 Welgen, Inc. Biderectional promoters for small rna expression
WO2005111219A1 (en) * 2004-04-16 2005-11-24 University Of Washington METHODS AND VECTORS FOR EXPRESSING siRNA

Also Published As

Publication number Publication date
US20090298909A1 (en) 2009-12-03
JP2008510489A (ja) 2008-04-10
US20120028348A1 (en) 2012-02-02
EP1784492A2 (de) 2007-05-16
EP2270161A2 (de) 2011-01-05
EP2270161A3 (de) 2011-02-02
DE602005024015D1 (de) 2010-11-18
WO2006033756A3 (en) 2007-01-18
EP2169072A1 (de) 2010-03-31
AU2005287365B2 (en) 2011-02-10
WO2006033756A2 (en) 2006-03-30
AU2005287365A1 (en) 2006-03-30
JP4804467B2 (ja) 2011-11-02
CA2577519A1 (en) 2006-03-30
US7985581B2 (en) 2011-07-26
EP1784492B1 (de) 2010-10-06

Similar Documents

Publication Publication Date Title
ATE483815T1 (de) Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren
Wang et al. Complete genome sequence of bacteriophage T5
ATE528402T1 (de) Effiziente genabschaltung in pflanzen unter verwendung von kurzen dsrna-sequenzen
JP2014514921A5 (de)
JP2015142558A5 (de)
JP2005517427A5 (de)
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
JP2019503394A5 (de)
RU2017130143A (ru) Гибридные днк/рнк-полинукдеотиды crispr и способы
JP2017093448A5 (de)
JP2024531728A5 (de)
DK2021472T3 (da) Forbindelser og fremgangsmåder til modulering af genekspression
ATE551420T1 (de) Gentransfer und expression mit hoher effizienz in säugerzellen mittels eines mehrfachtransfektionsverfahrens von matrixbindungsbereichsequenzen
JP2006502694A5 (de)
NZ599237A (en) Sirna compounds comprising terminal substitutions
MX2011007693A (es) Metodos para amplificar acidos nucleicos del virus de hepatitis c.
NZ563845A (en) RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
US20220348909A1 (en) Allosteric Conditional Guide RNAs for Cell-Selective Regulation of CRISPR/Cas
JP2005511055A5 (de)
JP2024500036A5 (de)
EA201070108A1 (ru) Cd44 сплайс-варианты в нейродегенеративных заболеваниях
JP2008500817A5 (ja) Ｄｎａウイルスのマイクロｒｎａ及びそれを阻害する医薬品
DE602004032245D1 (de) Genabschaltung (Gene silencing) durch hybride Sens-DNA und Antisens-RNA Konstrukte, gekoppelt an ein Peptid zur erleichterten Aufnahme in Zellen
WO2004044134A3 (en) Phosphorous-linked oligomeric compounds and their use in gene modulation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties